Seminars in Oncology
Volume 35, Issue 6 , Pages 590-596 , December 2008

Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options

  • Nilesh Vora

      Affiliations

    • Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, CA
    • ,
  • Karen L. Reckamp

      Affiliations

    • Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, CA
    • Department of Hematology & Hematopoeitic Transplantation Medicine, City of Hope and Beckman Research Institute, Duarte, CA
    • Corresponding Author InformationAddress correspondence to Karen L. Reckamp, MD, City of Hope, 1500 E Duarte Rd, MOB 1001 Duarte, CA 91010

References 

  1. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–5577
  2. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–2792
  3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  4. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated?. Lancet. 1990;335:1020–1022
  5. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067
  6. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? (Results of a pooled analysis from the North Central Cancer Treatment Group). J Clin Oncol. 2005;23:9113–9119
  7. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J. 2006;36:216–220
  8. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726
  9. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer (An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature). Lung Cancer. 2005;47:385–394
  10. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064–1070
  11. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–372
  12. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. [abstract] J Natl Cancer Inst. 2002;94:173–181
  13. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23:3125–3137
  14. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32
  15. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26:54–59
  16. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol. 2007;25:1898–1907
  17. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  18. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  19. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  20. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007;25:1553–1561
  21. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  22. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  23. Langer C, Hsu C, Curran WJ, Komaki R, Lee JS, Byhardt R, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. [abstract 1193] Proc Am Soc Clin Oncol. 2002;21:
  24. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–3206
  25. Rocha Lima CM, Herndon JE, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002;94:181–187
  26. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  28. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer (The Elderly Lung Cancer Vinorelbine Italian Study Group). J Natl Cancer Inst. 1999;91:66–72
  29. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–3663
  30. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer (A Southern Italy Cooperative Oncology Group (SICOG) phase III trial). Lung Cancer. 2001;34(Suppl 4):S65–S69
  31. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23:6865–6872
  32. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007;110:2027–2034
  33. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol. 2008;26:60–65
  34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  35. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–766
  36. Oxnard GR, Fidias P, Muzikansky A, et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol. 2007;2:1029–1035
  37. Kurishima K, Satoh H, Ishikawa H, et al. Lung cancer in the octogenarian. Gerontology. 2001;47:158–160

 Supported in part by Grant No. K12 CA 01727 from the National Cancer Institute and by the Phase One Foundation (K.L.R.). K.L. Reckamp has received honoraria from Genentech and Eli Lilly.

PII: S0093-7754(08)00192-9

doi: 10.1053/j.seminoncol.2008.08.009

Seminars in Oncology
Volume 35, Issue 6 , Pages 590-596 , December 2008

Article Tools